Avantis Medical Systems, a technology provider in developing catheter-mounted digital imaging devices, has presented five new studies confirming that use of Third Eye Retroscope during colonoscopy procedures increases detection of adenomas and polyps.

According to Avantis, the studies showed that physicians were able to detect adenomas of all sizes in elderly and young patients using the Third Eye.

In a study entitled, ‘Single-Center Evaluation Of The Third Eye Retroscope: A Back-To-Back Study,’ (M1513), Dr Anke Leufkens, Universitair Medisch Centrum-Utrecht, Utrecht, The Netherlands, concluded that colonoscopy with the Third Eye Retroscope detected more polyps compared to colonoscopy alone. Results were from one center participating in the multi-center Third Eye Retroscope Randomized Clinical Evaluation (TERRACE) study.

Dr Bradley Creel, Baylor University Medical Center, Dallas, TX, who participated in the same TERRACE study, presented a study entitled, “Polyp Detection With A Retrograde-Viewing Device: A Tandem Colonoscopy Study,” (S1590), concluding that the Third Eye Retroscope can reveal polyps that are hidden from the forward-viewing colonoscope.

Led by Dr Kapil Gupta, Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, MN, in a study entitled, “Effectiveness Of Third Eye Retroscope In Detection Of Colonic Adenomas In Elderly Patients (greater than or equal to 65 Years)” (S1133), researchers concluded that the Third Eye is effective in detecting clinically significant medium and large-sized adenomas in addition to small adenomas and that the device provides at least as much benefit for patients older than 65 years of age as it does for younger patients.

Dr Manoj Mehta, NorthShore University HealthSystem, Evanston, IL, presented poster S1597, entitled, “Impact Of Endoscopist’s Cumulative Years Of Experience On Baseline Adenoma Detection Rates And Additional Yield Utilizing The Third Eye Retroscope.” Endoscopists were divided into groups based upon colonoscopy experience. The physicians with 11 – 20 years’ experience showed the highest yield for baseline adenoma detection and improved detection rates when using the Third Eye Retroscope along with the colonoscope.

Dr Luis Lara, Baylor University Medical Center, presented, “Effects Of Indication For Colonoscopy And Time Since Previous Colonoscopy On Adenoma Detection Rates Using The Third Eye Retroscope” (S1593), concluding that use of the Third Eye Retroscope increased detection rates for adenomas and all polyps regardless of whether the indication for the procedure was for screening, for surveillance in follow-up of previous polypectomy or for diagnostic work-up of symptomatic patients.

Avantis said that the Utrecht site analyzed 46 patients divided between two groups where the first group underwent a first procedure with the colonoscope alone and a second procedure with the colonoscope along with Third Eye Retroscope. The other group had Third Eye colonoscopy followed by a second procedure with the colonoscope alone. Compared to using the colonoscope alone, the Third Eye Retroscope improved detection rates by 82.8% for all polyps and 53.2% for adenomas.

Avantis also reported the launch of its Third Eye Retroscope, which offers improved optical resolution, a smaller profile that allows the Third Eye camera and catheter to be introduced into accessory channels of even the smallest available colonoscopes and PAL video standard compatibility for use within markets outside of the US.

Scott Dodson, president and CEO of Avantis Medical, said: “Over the last few years, Avantis has worked closely with leading gastroenterologists from around the world to produce a portfolio of quality clinical data that we believe supports broader adoption of the Third Eye as an essential complement to colonoscopy. We look forward to seeing the Third Eye playing a greater role in helping to reduce the incidence of colorectal cancer.”

Jack Higgins, chief medical officer of Avantis Medical, said: “These data confirm that the Third Eye Retroscope improves adenoma detection rates during colonoscopy, the current gold standard for colon cancer screening. These data, combined with an already large body of well-controlled clinical trial data, validate the Third Eye Retroscope’s potential as an essential tool in colorectal cancer screening.”